Загрузка...
Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry
Background: Moderate and high efficacy disease modifying therapies (DMTs) have a profound effect on disease activity. The current treatment guidelines only recommend high efficacy DMTs for patients with highly active MS. The objective was to examine the impact of initial treatment choice in achievin...
Сохранить в:
| Опубликовано в: : | Front Neurol |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8248666/ https://ncbi.nlm.nih.gov/pubmed/34220694 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2021.693017 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|